Disc Medicine discloses ITGC material weakness; outlines bitopertin NDA plan and 2025 milestones

Disc Medicine, Inc.

Material weakness in ITGC over key financial IT systems; no misstatements identified to date.
Bitopertin NDA submission plans to be discussed after Type C FDA meeting in Q1 2025; potential accelerated approval for EPP.
Initial phase 2 data for DISC-0974 in myelofibrosis anemia expected H2 2025; multiple-dose CKD data also H2 2025.
Phase 2 trial of DISC-3405 in polycythemia vera planned to start H1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.